Hacker News Reader

To add to this, I worked in melanoma genomics for 2 years. Off the top of my head I cannot think of a single cancer drug on the market who's target was discovered through NGS.

It was great as a research tool. But I have yet to see it improve patient outcomes

View on HN

It's not quite _discovering_ a target from NGS, but lots of existing cancer drugs are targeted based on genotyping tumours. Breast cancer is the classic one, where, say, if you can quickly determine if your sample is Her2+ your treatment plan drastically changes. Now, getting enough cancer cells in your tumour sample to reliably genotype at that stage is a separate hard problem.

Reply on news.ycombinator.com